Last10K.com

Anixa Biosciences Inc (ANIX) SEC Filing 10-K Annual Report for the fiscal year ending Monday, October 31, 2022

Anixa Biosciences Inc

CIK: 715446 Ticker: ANIX
Cover - USD ($)
12 Months Ended
Oct. 31, 2022
Jan. 05, 2023
Apr. 29, 2022
Cover [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Annual Reporttrue  
Document Transition Reportfalse  
Document Period End DateOct. 31, 2022  
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2022  
Current Fiscal Year End Date--10-31  
Entity File Number001-37492  
Entity Registrant NameANIXABIOSCIENCES, INC.  
Entity Central Index Key0000715446  
Entity Tax Identification Number11-2622630  
Entity Incorporation, State or Country CodeDE  
Entity Address, Address Line One3150Almaden Expressway  
Entity Address, Address Line TwoSuite 250  
Entity Address, City or TownSanJose  
Entity Address, State or ProvinceCA  
Entity Address, Postal Zip Code95118  
City Area Code(408)  
Local Phone Number708-9808  
Title of 12(b) SecurityCommon Stock, $0.01 par value  
Trading SymbolANIX  
Security Exchange NameNASDAQ  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Interactive Data CurrentYes  
Entity Filer CategoryNon-accelerated Filer  
Entity Small Businesstrue  
Entity Emerging Growth Companyfalse  
Entity Shell Companyfalse  
Entity Public Float  $ 93,235,194
Entity Common Stock, Shares Outstanding 30,920,792 
Documents Incorporated by Reference [Text Block]NONE  
ICFR Auditor Attestation Flagfalse  
Auditor Firm ID200  
Auditor NameHASKELL& WHITE LLP  
Auditor LocationIrvine,California  

View differences made from one year to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Anixa Biosciences Inc.

Continue

Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
Other
Filter Subcategory:
All
Product
Cash Flow
Expense
Other
Inside Anixa Biosciences Inc's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Cover
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Equity
Consolidated Statements Of Equity (Parenthetical)
Consolidated Statements Of Operations
Consolidated Statements Of Operations (Parenthetical)
Accrued Expenses
Accrued Expenses (Tables)
Business And Funding
Business And Funding (Details Narrative)
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Income Taxes
Income Taxes (Details Narrative)
Income Taxes (Tables)
Leases
Leases (Details Narrative)
Leases (Tables)
Public Offering
Public Offering (Details Narrative)
Schedule Of Accrued Expenses (Details)
Schedule Of Changes In Noncontrolling Interest (Details)
Schedule Of Deferred Tax Assets And Liabilities (Details)
Schedule Of Hierarchy Of Financial Assets (Details)
Schedule Of Income Tax Provision (Benefit) (Details)
Schedule Of Minimum Lease Payments (Details)
Schedule Of Option Activity (Details)
Schedule Of Outstanding And Exercisable (Details)
Schedule Of Reconciliation Of Income Taxes (Details)
Schedule Of Segment Information (Details)
Schedule Of Warrants Activity (Details)
Schedule Of Weighted Average Assumptions Used In Estimating Fair Value Of Stock Options (Details)
Segment Information
Segment Information (Details Narrative)
Segment Information (Tables)
Shareholders??? Equity
Shareholders??? Equity (Details Narrative)
Shareholders??? Equity (Tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details Narrative)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Ticker: ANIX
CIK: 715446
Form Type: 10-K Annual Report
Accession Number: 0001493152-23-000346
Submitted to the SEC: Wed Jan 04 2023 4:59:57 PM EST
Accepted by the SEC: Wed Jan 04 2023
Period: Monday, October 31, 2022
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anix/0001493152-23-000346.htm